ABSCI CORP Operating Cash Flow
ABSCI CORP (ABSI) reported Operating Cash Flow of -$53.87 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-11
- ABSCI CORP net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$27.56M.
- ABSCI CORP net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$26.31M.
- ABSCI CORP net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$29.18M.
- ABSCI CORP net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$25.03M.
- ABSCI CORP net cash provided by (used in) operating activities for fiscal 2025 was -$92.92M.
- ABSCI CORP net cash provided by (used in) operating activities for fiscal 2024 was -$72.40M.
- ABSCI CORP net cash provided by (used in) operating activities for fiscal 2023 was -$64.64M.
- ABSCI CORP net cash provided by (used in) operating activities for fiscal 2022 was -$81.34M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$27.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$53.87M 10-Q · filed 2026-08-11 | -$83.05M derived: sum of 3 quarters · filed 2026-08-11 | -$108.08M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$26.31M 10-Q · filed 2026-05-07 | -$55.49M derived: sum of 2 quarters · filed 2026-05-07 | -$80.52M derived: sum of 3 quarters · filed 2026-05-07 | -$97.39M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$29.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$54.21M derived: sum of 2 quarters · filed 2026-03-24 | -$71.09M derived: sum of 3 quarters · filed 2026-08-11 | -$92.92M 10-K · filed 2026-03-24 |
| 2025-09-30 | -$25.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$41.90M derived: sum of 2 quarters · filed 2026-08-11 | -$63.74M 10-Q · filed 2025-11-12 | -$80.71M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$16.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$38.71M 10-Q · filed 2026-08-11 | -$55.68M derived: sum of 3 quarters · filed 2026-08-11 | -$76.41M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$21.84M 10-Q · filed 2026-05-07 | -$38.80M derived: sum of 2 quarters · filed 2026-05-07 | -$59.53M derived: sum of 3 quarters · filed 2026-05-07 | -$76.38M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$16.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$37.70M derived: sum of 2 quarters · filed 2026-03-24 | -$54.54M derived: sum of 3 quarters · filed 2026-03-24 | -$72.40M 10-K · filed 2026-03-24 |
| 2024-09-30 | -$20.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$37.58M derived: sum of 2 quarters · filed 2025-11-12 | -$55.44M 10-Q · filed 2025-11-12 | -$70.36M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$16.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$34.71M 10-Q · filed 2025-08-12 | -$49.63M derived: sum of 3 quarters · filed 2025-08-12 | -$59.99M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$17.86M 10-Q · filed 2025-05-13 | -$32.78M derived: sum of 2 quarters · filed 2025-05-13 | -$43.15M derived: sum of 3 quarters · filed 2025-05-13 | -$62.38M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$14.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | -$25.28M derived: sum of 2 quarters · filed 2025-03-18 | -$44.52M derived: sum of 3 quarters · filed 2025-03-18 | -$64.64M 10-K · filed 2025-03-18 |
| 2023-09-30 | -$10.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$29.59M derived: sum of 2 quarters · filed 2024-11-12 | -$49.71M 10-Q · filed 2024-11-12 | -$68.28M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$19.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$39.35M 10-Q · filed 2024-08-14 | -$57.92M derived: sum of 3 quarters · filed 2024-08-14 | -$76.96M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$20.12M 10-Q · filed 2024-05-14 | -$38.69M derived: sum of 2 quarters · filed 2024-05-14 | -$57.73M derived: sum of 3 quarters · filed 2024-05-14 | -$80.31M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$18.57M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$37.61M derived: sum of 2 quarters · filed 2024-03-21 | -$60.19M derived: sum of 3 quarters · filed 2024-03-21 | -$81.34M 10-K · filed 2024-03-21 |
| 2022-09-30 | -$19.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$41.62M derived: sum of 2 quarters · filed 2023-11-14 | -$62.77M 10-Q · filed 2023-11-14 | -$79.85M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$22.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$43.73M 10-Q · filed 2023-08-14 | -$60.81M derived: sum of 3 quarters · filed 2023-08-14 | -$82.55M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$21.15M 10-Q · filed 2023-05-15 | -$38.23M derived: sum of 2 quarters · filed 2023-05-15 | -$59.98M derived: sum of 3 quarters · filed 2023-05-15 | -$74.46M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$17.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$38.83M derived: sum of 2 quarters · filed 2023-03-30 | -$53.31M derived: sum of 3 quarters · filed 2023-03-30 | -$60.60M 10-K · filed 2023-03-30 |
| 2021-09-30 | -$21.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$36.23M derived: sum of 2 quarters · filed 2022-11-09 | -$43.52M 10-Q · filed 2022-11-09 | -$46.04M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$14.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$21.77M 10-Q · filed 2022-08-11 | -$24.29M derived: sum of 3 quarters · filed 2022-08-11 | -$27.00M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$7.29M 10-Q · filed 2022-05-11 | -$9.81M derived: sum of 2 quarters · filed 2022-05-11 | -$12.51M derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | -$2.52M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | -$5.23M derived: sum of 2 quarters · filed 2022-03-22 | -$10.97M 10-K · filed 2022-03-22 | |
| 2020-09-30 | -$2.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$8.45M 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | -$5.74M 10-Q · filed 2021-09-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |